{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:51:55Z","timestamp":1767340315558,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Neurovirol."],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s13365-019-00821-3","type":"journal-article","created":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T18:02:46Z","timestamp":1575568966000},"page":"437-441","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Epilepsia partialis continua revealing idelalisib-associated PML-IRIS: clinical and pathological features"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3652-7061","authenticated-orcid":false,"given":"Alberto","family":"Vogrig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian Luigi","family":"Gigli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annacarmen","family":"Nilo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Elena","family":"Pessa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Volpetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Pegolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariarosaria","family":"Valente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,5]]},"reference":[{"key":"821_CR1","doi-asserted-by":"publisher","first-page":"5558","DOI":"10.1038\/s41598-018-23808-2","volume":"8","author":"A Alflen","year":"2018","unstructured":"Alflen A, Stadler N, Aranda Lopez P, Teschner D, Theobald M, He\u00df G, Radsak MP (2018) Idelalisib impairs TREM-1 mediated neutrophil inflammatory responses. Sci Rep 8:5558. https:\/\/doi.org\/10.1038\/s41598-018-23808-2","journal-title":"Sci Rep"},{"key":"821_CR2","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1001\/jamaneurol.2014.825","volume":"71","author":"KB Alstadhaug","year":"2014","unstructured":"Alstadhaug KB, Croughs T, Henriksen S, Leboeuf C, Sereti I, Hirsch HH, Rinaldo CH (2014) Treatment of progressive multifocal leukoencephalopathy with interleukin 7. JAMA Neurol 71:1030\u20131035. https:\/\/doi.org\/10.1001\/jamaneurol.2014.825","journal-title":"JAMA Neurol"},{"key":"821_CR3","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1212\/WNL.0000000000001804","volume":"85","author":"D Andriuta","year":"2015","unstructured":"Andriuta D, Tir M, Perin B, Merle PE, Bryer-le Breton C, Charbonnier A, Constans JM, Godefroy O (2015) Teaching NeuroImages: epilepsia partialis continua revealing PML after allogenic stem cell transplantation. Neurology 85:e53\u2013e54. https:\/\/doi.org\/10.1212\/WNL.0000000000001804","journal-title":"Neurology"},{"key":"821_CR4","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00401-015-1471-7","volume":"130","author":"J Bauer","year":"2015","unstructured":"Bauer J, Gold R, Adams O, Lassmann H (2015) Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS). Acta Neuropathol 130:751\u2013764. https:\/\/doi.org\/10.1007\/s00401-015-1471-7","journal-title":"Acta Neuropathol"},{"key":"821_CR5","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/mds.10599","volume":"18","author":"J Berciano","year":"2003","unstructured":"Berciano J, Leno C, Figols J, Garc\u00eda A, Polo JM, Berciano MT, Ariza A (2003) Epilepsia partialis continua in progressive multifocal leukoencephalopathy: a motor cortex isolation syndrome. Mov Disord 18:1559\u20131564. https:\/\/doi.org\/10.1002\/mds.10599","journal-title":"Mov Disord"},{"key":"821_CR6","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","volume":"80","author":"JR Berger","year":"2013","unstructured":"Berger JR, Aksamit AJ, Clifford DB, Davis L, Koralnik IJ, Sejvar JJ, Bartt R, Major EO, Nath A (2013) PML diagnostic criteria: consensus statement from the AAN Neuroinfectious disease section. Neurology 80:1430\u20131438. https:\/\/doi.org\/10.1212\/WNL.0b013e31828c2fa1","journal-title":"Neurology"},{"key":"821_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1684\/epd.2008.0161","volume":"10","author":"CG Bien","year":"2008","unstructured":"Bien CG, Elger CE (2008) Epilepsia partialis continua: semiology and differential diagnoses. Epileptic Disord 10:3\u20137. https:\/\/doi.org\/10.1684\/epd.2008.0161","journal-title":"Epileptic Disord"},{"key":"821_CR8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1684\/epd.2018.0983","volume":"20","author":"F Brigo","year":"2018","unstructured":"Brigo F, Vogrig A, Bratti A et al (2018) Probable dysimmune epilepsia partialis continua manifesting as epileptic moving toes syndrome: electroclinical features of a challenging case. Epileptic Disord 20:301\u2013312. https:\/\/doi.org\/10.1684\/epd.2018.0983","journal-title":"Epileptic Disord"},{"issue":"Pt 2","key":"821_CR9","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/brain\/119.2.393","volume":"119","author":"OC Cockerell","year":"1996","unstructured":"Cockerell OC, Rothwell J, Thompson PD et al (1996) Clinical and physiological features of epilepsia partialis continua. Cases ascertained in the UK. Brain 119(Pt 2):393\u2013407","journal-title":"Brain"},{"key":"821_CR10","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S0022-510X(98)00281-0","volume":"161","author":"S Ferrari","year":"1998","unstructured":"Ferrari S, Monaco S, Morbin M, Zanusso G, Bertolasi L, Cerini R, Rizzuto N (1998) HIV-associated PML presenting as epilepsia partialis continua. J Neurol Sci 161:180\u2013184","journal-title":"J Neurol Sci"},{"key":"821_CR11","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1212\/WNL.0b013e318253d61e","volume":"78","author":"S Gheuens","year":"2012","unstructured":"Gheuens S, Smith DR, Wang X, Alsop DC, Lenkinski RE, Koralnik IJ (2012) Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS. Neurology 78:1390\u20131393. https:\/\/doi.org\/10.1212\/WNL.0b013e318253d61e","journal-title":"Neurology"},{"key":"821_CR12","unstructured":"Health Canada (2017) Summary Safety Review-ZYDELIG (idelalisib)-assessing the potential risk of a rare brain infection (progressive multifocal leukoencephalopathy). In: aem. https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/medeffect-canada\/safety-reviews\/zydelig-assessing-potential-risk-rare-brain-infection.html. Accessed 10 Sept 2019"},{"key":"821_CR13","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/s41375-019-0388-x","volume":"33","author":"G Maschmeyer","year":"2019","unstructured":"Maschmeyer G, De Greef J, Mellinghoff SC et al (2019) Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European conference on infections in Leukemia (ECIL). Leukemia 33:844\u2013862. https:\/\/doi.org\/10.1038\/s41375-019-0388-x","journal-title":"Leukemia"},{"key":"821_CR14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00401-011-0900-5","volume":"123","author":"I Metz","year":"2012","unstructured":"Metz I, Radue E-W, Oterino A, K\u00fcmpfel T, Wiendl H, Schippling S, Kuhle J, Sahraian MA, Gray F, Jakl V, H\u00e4usler D, Br\u00fcck W (2012) Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy. Acta Neuropathol 123:235\u2013245. https:\/\/doi.org\/10.1007\/s00401-011-0900-5","journal-title":"Acta Neuropathol"},{"key":"821_CR15","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1001\/archneurol.2010.257","volume":"68","author":"A Miravalle","year":"2011","unstructured":"Miravalle A, Jensen R, Kinkel RP (2011) Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol 68:186\u2013191. https:\/\/doi.org\/10.1001\/archneurol.2010.257","journal-title":"Arch Neurol"},{"key":"821_CR16","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1056\/NEJMoa1801540","volume":"379","author":"M Muftuoglu","year":"2018","unstructured":"Muftuoglu M, Olson A, Marin D et al (2018) Allogeneic BK virus-specific T cells for progressive multifocal leukoencephalopathy. N Engl J Med 379:1443\u20131451. https:\/\/doi.org\/10.1056\/NEJMoa1801540","journal-title":"N Engl J Med"},{"key":"821_CR17","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1080\/10428194.2018.1457147","volume":"59","author":"C Pleyer","year":"2018","unstructured":"Pleyer C, Wiestner A, Sun C (2018) Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia. Leuk Lymphoma 59:2792\u20132800. https:\/\/doi.org\/10.1080\/10428194.2018.1457147","journal-title":"Leuk Lymphoma"},{"key":"821_CR18","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1080\/14740338.2016.1198775","volume":"15","author":"DW Raisch","year":"2016","unstructured":"Raisch DW, Rafi JA, Chen C, Bennett CL (2016) Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA\u2019s adverse event reporting system. Expert Opin Drug Saf 15:1003\u20131011. https:\/\/doi.org\/10.1080\/14740338.2016.1198775","journal-title":"Expert Opin Drug Saf"},{"key":"821_CR19","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","volume":"9","author":"CS Tan","year":"2010","unstructured":"Tan CS, Koralnik IJ (2010) Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 9:425\u2013437. https:\/\/doi.org\/10.1016\/S1474-4422(10)70040-5","journal-title":"Lancet Neurol"},{"key":"821_CR20","doi-asserted-by":"publisher","unstructured":"Vogrig A, Joubert B, Andr\u00e9-Obadia N et al (2019) Seizure specificities in patients with antibody-mediated autoimmune encephalitis. Epilepsia. https:\/\/doi.org\/10.1111\/epi.16282","DOI":"10.1111\/epi.16282"},{"key":"821_CR21","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1056\/NEJMc1816198","volume":"380","author":"O Walter","year":"2019","unstructured":"Walter O, Treiner E, Bonneville F et al (2019) Treatment of progressive multifocal Leukoencephalopathy with nivolumab. N Engl J Med 380:1674\u20131676. https:\/\/doi.org\/10.1056\/NEJMc1816198","journal-title":"N Engl J Med"}],"container-title":["Journal of NeuroVirology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-019-00821-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13365-019-00821-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-019-00821-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T12:54:01Z","timestamp":1659099241000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13365-019-00821-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,5]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["821"],"URL":"https:\/\/doi.org\/10.1007\/s13365-019-00821-3","relation":{},"ISSN":["1355-0284","1538-2443"],"issn-type":[{"type":"print","value":"1355-0284"},{"type":"electronic","value":"1538-2443"}],"subject":[],"published":{"date-parts":[[2019,12,5]]},"assertion":[{"value":"30 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All procedures were performed in accordance with the institutional ethics committee and the Declaration of Helsinki. A written informed consent was obtained for publication of this case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}